InDex Pharmaceuticals – Mechanism of Action for Cobitolimod
Watch our live event with CEO Peter Zerhouni and immunologist Charlotte Admyre from InDex Pharmaceutials.
InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. InDex Pharmaceuticals lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex Pharmaceuticals has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.
Tune in when Charlotte Admyre dive into the mechanism of action with Cobitolimod. Cobitolimod is in clinical phase 3 and InDex Pharmaceuticals lead drug candidate in development for the treatment of moderate to severe ulcerative colitis.
During the event CEO Peter Zerhouni will briefly present the Full year report.
InDex Pharmaceuticals is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.
Disclaimer: HC Andersen Capital receives payment from Index Pharmaceuticals for a Digital IR / Corporate Visibility subscription agreement.